Is Arcus Biosciences, Inc. (RCUS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.2% / 30% | 35.3% / 30% | 0.9% / 30% | 20.16% / 5% | ✗ NOT HALAL |
| DJIM | 2.2% / 33% | 35.3% / 33% | 0.9% / 33% | 20.16% / 5% | ✗ NOT HALAL |
| MSCI | 5.2% / 33% | 85.0% / 33% | 2.2% / 33% | 20.16% / 5% | ✗ NOT HALAL |
| S&P | 2.2% / 33% | 35.3% / 33% | 0.9% / 33% | 20.16% / 5% | ✗ NOT HALAL |
| FTSE | 5.2% / 33% | 85.0% / 33% | 2.2% / 50% | 20.16% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -111.7% | |
| Operating Margin | -345.5% | |
| Net Margin | -142.9% | |
| Return on Equity (ROE) | -63.3% | |
| Return on Assets (ROA) | -21.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$482M |
| Free Cash Flow | -$484M |
| Total Debt | $112M |
| Debt-to-Equity | 34.7 |
| Current Ratio | 4.4 |
| Total Assets | $1.1B |
Price & Trading
| Last Close | $21.21 |
| 50-Day MA | $21.48 |
| 200-Day MA | $16.80 |
| Avg Volume | 1.3M |
| Beta | 0.9 |
|
52-Week Range
$6.50
| |
About Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Arcus Biosciences, Inc. (RCUS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Arcus Biosciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Arcus Biosciences, Inc.'s debt ratio?
Arcus Biosciences, Inc.'s debt ratio is 2.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.2%.
What are Arcus Biosciences, Inc.'s key financial metrics?
Arcus Biosciences, Inc. has a market capitalization of $2.5B, and revenue of $247M. The company maintains a gross margin of -111.7% and a net margin of -142.9%. Return on equity stands at -63.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.